Whole Genome Sequencing in Irish Multiplex Schizophrenia Families

Information

  • Research Project
  • 10252765
  • ApplicationId
    10252765
  • Core Project Number
    R01MH114593
  • Full Project Number
    5R01MH114593-05
  • Serial Number
    114593
  • FOA Number
    PA-16-160
  • Sub Project Id
  • Project Start Date
    9/4/2017 - 6 years ago
  • Project End Date
    6/30/2022 - a year ago
  • Program Officer Name
    GITIK, MIRI
  • Budget Start Date
    7/1/2021 - 2 years ago
  • Budget End Date
    6/30/2022 - a year ago
  • Fiscal Year
    2021
  • Support Year
    05
  • Suffix
  • Award Notice Date
    8/31/2021 - 2 years ago

Whole Genome Sequencing in Irish Multiplex Schizophrenia Families

Project Summary: Although affected members of multiplex schizophrenia pedigrees have substantially elevated recurrence risk compared to singleton cases, the mean polygenic risk scores between these groups do not differ, suggesting that one source of this higher familial recurrence risk is rare, higher impact variation. We will collect whole genome sequence (WGS) from 600 affected members of multiplex schizophrenia pedigrees to identify rare variation shared by affected individuals within and between pedigrees potentially accounting for the increased recurrence risk, and reducing the `variant space' under consideration. After QC and calling in our existing pipeline, a) familial sequence variants in the exome will be directly analyzed in 2000 Irish cases and 2000 Irish controls with 30X exome sequence data in production currently, and b) variants outside the exome will be imputed into 3600 Irish singleton schizophrenia or bipolar disorder cases and 3000 Irish population controls with GWAS framework data; 3781 additional UK10K controls with 10X WGS are available to increase analysis power. This imputed dataset will be analyzed using recently developed methods for kernel-based tests of variation aggregated over a defined interval (such as a gene) that avoid the inflation of type-1 error. We use multiple sources of genomic information to develop weights for each position in the genome (indexing the prior probability that a change at the site has functional consequence) and each variant detected (indexing the probability that observed changes have functional consequence), and we propose to improve the existing genomic information sources for this weighting in a number of ways. In aim 3, prioritized variants from aim 2a/2b will be directly genotyped in the case/control samples by custom microarray; individual genes or genesets showing enrichment of variation in cases (if any are observed) will be resequenced in the case/control sample. In Aim 4, the directly assessed genotypic and sequence data from aim 3 will be analyzed using standard methods to identify individual associated variants, and variant-enriched genes, genesets or other functional sequences. We seek to unambiguously identify 1) individual variants that are significantly more common in cases, or 2) individual genes or other functional sequences or 3) gene- or functional sequence sets enriched for variation in cases to provide critical information about the brain systems perturbed in schizophrenia, and the mechanisms by which such alleles increase risk.

IC Name
NATIONAL INSTITUTE OF MENTAL HEALTH
  • Activity
    R01
  • Administering IC
    MH
  • Application Type
    5
  • Direct Cost Amount
    286646
  • Indirect Cost Amount
    112891
  • Total Cost
    399537
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    242
  • Ed Inst. Type
    SCHOOLS OF MEDICINE
  • Funding ICs
    NIMH:399537\
  • Funding Mechanism
    Non-SBIR/STTR RPGs
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    VIRGINIA COMMONWEALTH UNIVERSITY
  • Organization Department
    PSYCHIATRY
  • Organization DUNS
    105300446
  • Organization City
    RICHMOND
  • Organization State
    VA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    232980568
  • Organization District
    UNITED STATES